GlaxoSmithKline’s ‘serial disappointments’ cast doubt on its growth plans: analyst
Between the failure of its late-stage cancer drug bintrafusp alfa in a key clinical trial and an unexpected inspection delay for another oncology hopeful, dostarlimab, GlaxoSmithKline is having a bad week,…
Continue reading